Ascelia: Q2 following the required re-evaluation of the SPARKLE study - Redeye

The FDA feedback later this year will be very important. If it is enough with a revaluation based on new readers the financial challenge is significant. If FDA asks for a new and modified study Ascelia's financial and clinical challenge is of course even tougher. Secondly we look forward to Ascelia's expected planned mid-September update regarding the timelines and the financial implications by mid-September. The Q2 feedback includes an operating cash burn of SEK 42.3m and a cash balance of SEK 70.5m as of end June.

Länk till analysen i sin helhet: https://www.redeye.se/research/934782/ascelia-q2-following-the-required-re-evaluation-of-the-sparkle-study?utm_source=finwire&utm_medium=RSS